The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback